Compare Stocks → Your $200 account credit is about to expire (From MarketBeat) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKBANASDAQ:NKTRNASDAQ:RAPTNASDAQ:VTYX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.15+0.9%$1.52$0.78▼$2.48$238.94M0.943.03 million shs2.39 million shsNKTRNektar Therapeutics$1.76-2.8%$1.29$0.41▼$1.93$330.52M0.711.67 million shs1.14 million shsRAPTRAPT Therapeutics$4.04-2.4%$7.75$3.98▼$27.35$144.50M0.52972,990 shs542,364 shsVTYXVentyx Biosciences$4.73-5.0%$5.43$1.87▼$40.58$351.09M0.48945,360 shs510,503 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+0.88%-4.96%-17.27%-20.69%+1.77%NKTRNektar Therapeutics-2.50%-0.28%+30.00%+146.52%+150.71%RAPTRAPT Therapeutics-2.42%-6.70%-49.75%-84.44%-80.81%VTYXVentyx Biosciences-5.02%+15.65%+7.99%+92.28%-86.39%Automatic Income (from home) (Ad)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short videoMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.1641 of 5 stars3.54.00.04.02.60.80.6NKTRNektar Therapeutics4.1498 of 5 stars3.03.00.04.23.22.50.6RAPTRAPT Therapeutics3.934 of 5 stars4.22.00.03.61.01.70.6VTYXVentyx Biosciences2.2151 of 5 stars3.32.00.00.02.54.20.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics3.00Buy$5.00334.78% UpsideNKTRNektar Therapeutics2.00Hold$3.5099.43% UpsideRAPTRAPT Therapeutics2.31Hold$24.67510.56% UpsideVTYXVentyx Biosciences2.56Moderate Buy$21.75359.83% UpsideCurrent Analyst RatingsLatest AKBA, VTYX, RAPT, and NKTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024RAPTRAPT TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Peer Perform5/10/2024RAPTRAPT TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/10/2024RAPTRAPT TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$13.00 ➝ $4.004/10/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/28/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.003/27/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.003/15/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/13/2024VTYXVentyx BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.003/12/2024VTYXVentyx BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$12.003/12/2024VTYXVentyx BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$7.00 ➝ $16.003/6/2024NKTRNektar TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$0.50 ➝ $1.00(Data available from 5/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$194.62M1.24N/AN/A($0.13) per share-8.85NKTRNektar Therapeutics$90.12M3.58N/AN/A$0.69 per share2.54RAPTRAPT Therapeutics$1.53M92.15N/AN/A$3.75 per share1.08VTYXVentyx BiosciencesN/AN/AN/AN/A$4.35 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.23N/AN/AN/A-22.99%N/A-18.01%8/23/2024 (Estimated)NKTRNektar Therapeutics-$276.06M-$0.92N/AN/AN/A-195.02%-107.31%-38.08%8/13/2024 (Estimated)RAPTRAPT Therapeutics-$116.80M-$3.07N/AN/AN/AN/A-72.61%-62.99%8/9/2024 (Estimated)VTYXVentyx Biosciences-$192.96M-$3.24N/AN/AN/AN/A-65.94%-59.87%8/8/2024 (Estimated)Latest AKBA, VTYX, RAPT, and NKTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024AKBAAkebia Therapeutics-$0.09-$0.09N/A-$0.09$41.13 million$32.61 million 5/9/2024Q1 2024NKTRNektar Therapeutics-$0.21-$0.18+$0.03-$0.17$14.91 million$21.64 million 5/9/2024Q1 2024VTYXVentyx Biosciences-$0.67-$0.62+$0.05-$0.62N/AN/A 3/14/2024Q4 2023AKBAAkebia Therapeutics-$0.04-$0.04N/AN/A$55.64 million$56.20 million3/7/2024Q4 2023RAPTRAPT Therapeutics-$0.85-$0.80+$0.05-$0.80N/AN/A3/4/202412/31/2023NKTRNektar Therapeutics-$0.21-$0.22-$0.01-$0.22$17.09 million$23.89 million 2/27/2024Q4 2023VTYXVentyx Biosciences-$0.87-$0.79+$0.08-$0.79N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.701.31NKTRNektar TherapeuticsN/A6.105.79RAPTRAPT TherapeuticsN/A7.017.01VTYXVentyx BiosciencesN/A22.0011.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%NKTRNektar Therapeutics75.88%RAPTRAPT Therapeutics99.09%VTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.84%NKTRNektar Therapeutics3.07%RAPTRAPT Therapeutics6.60%VTYXVentyx Biosciences24.39%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics167209.60 million201.55 millionOptionableNKTRNektar Therapeutics137183.62 million177.99 millionOptionableRAPTRAPT Therapeutics13134.90 million32.60 millionOptionableVTYXVentyx Biosciences7970.50 million53.30 millionOptionableAKBA, VTYX, RAPT, and NKTR HeadlinesRecent News About These CompaniesMay 16 at 4:05 PM | globenewswire.comVentyx Biosciences to Participate in Three Upcoming Investor ConferencesMay 16 at 10:20 AM | msn.comVentyx Biosciences gets new operations chiefMay 16 at 10:20 AM | markets.businessinsider.comVentyx Biosciences Appoints Moore As COOMay 16 at 8:00 AM | globenewswire.comVentyx Biosciences Announces Appointment of Matthew Moore as Chief Operating OfficerMay 16 at 5:20 AM | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Ventyx Biosciences (VTYX)May 13, 2024 | finance.yahoo.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comVentyx Biosciences (NASDAQ:VTYX) Announces Earnings ResultsMay 10, 2024 | markets.businessinsider.comBuy Rating for Ventyx Biosciences Based on Clinical and Financial StrengthsMay 10, 2024 | bovnews.comVentyx Biosciences Inc (VTYX) Stock is looking to regain its victoryMay 9, 2024 | investorplace.comVTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024May 9, 2024 | finance.yahoo.comVentyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate ProgressMay 8, 2024 | americanbankingnews.comVentyx Biosciences (VTYX) Set to Announce Quarterly Earnings on ThursdayMay 3, 2024 | marketbeat.comVentyx Biosciences (VTYX) Scheduled to Post Earnings on ThursdayMay 2, 2024 | globenewswire.comVentyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024April 30, 2024 | accesswire.comApril 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYXApril 30, 2024 | prnewswire.comVTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYXApril 30, 2024 | zacks.comWhat Makes Ventyx Biosciences (VTYX) a New Buy StockApril 30, 2024 | accesswire.comClass Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for Investors - Contact Levi & KorsinskyApril 30, 2024 | markets.businessinsider.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx BiosciencesApril 30, 2024 | accesswire.comShareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreApril 30, 2024 | accesswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYXNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkebia TherapeuticsNASDAQ:AKBAAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Nektar TherapeuticsNASDAQ:NKTRNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.RAPT TherapeuticsNASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyVentyx BiosciencesNASDAQ:VTYXVentyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.